Classification and grading of neuroendocrine neoplasm of digestive system
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Searching PubMed
neuroendocrine neoplasm digestive system WHO classification 2022
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.
Classification and Grading of Neuroendocrine Neoplasms (NENs) of the Digestive System
Neuroendocrine neoplasms (NENs) of the digestive system - which include tumors from the stomach, small intestine, appendix, colon, rectum, and pancreas - have undergone significant reclassification over the decades. The current framework is based primarily on the WHO 2010/2017/2022 classification and ENETS/NANETS grading systems.
1. Terminology
The older term "carcinoid tumor" has largely been replaced by more precise terminology, though it remains in common clinical use:
| Old Term | Current WHO Term |
|---|---|
| Carcinoid tumor | Neuroendocrine tumor (NET) |
| Islet cell tumor | Pancreatic NET (panNET) |
| Poorly differentiated carcinoid | Neuroendocrine carcinoma (NEC) |
| Mixed exocrine-endocrine tumor | MiNEN |
NEN is the umbrella term for the entire group, subdivided into:
- NET - well-differentiated neuroendocrine tumor
- NEC - poorly differentiated neuroendocrine carcinoma
- MiNEN - mixed neuroendocrine-non-neuroendocrine neoplasm
2. WHO Grading System (2017/2022)
Grade is determined by two parameters - mitotic count (per 10 high-power fields, HPF) and Ki-67 proliferation index (%). Whichever gives the higher grade takes precedence.
For Gastroenteropancreatic NETs (GEP-NETs):
| Grade | Mitotic Count (per 10 HPF) | Ki-67 Index | WHO Term |
|---|---|---|---|
| G1 (Low) | < 2 | < 3% | NET G1 |
| G2 (Intermediate) | 2-20 | 3-20% | NET G2 |
| G3 (High) | > 20 | > 20% | NET G3 (well-differentiated) |
| G3 (High) | > 20 | > 20% | NEC G3 (poorly differentiated) |
Key distinction: Both well-differentiated G3 NET and poorly differentiated NEC fall in the "high grade" category, but they are biologically and clinically distinct. G3 NET retains organoid architecture; G3 NEC shows sheets of pleomorphic cells with necrosis. G3 NETs have better survival than NECs and respond to different treatment modalities.
Evolution of Classification:
| Year | Key Change |
|---|---|
| 2000 WHO | First pathological/clinical criteria; categorized as benign, malignant, or uncertain behavior |
| 2006-2007 ENETS | Introduced TNM staging + proliferation-based grading |
| 2010 WHO | Adopted grading (G1, G2, G3); only G1/G2 were well-differentiated |
| 2017 WHO (pancreas) | Added well-differentiated G3 NET as separate entity |
| 2022 WHO | Further refinement; recognized G3 NET/NEC distinction across all GI sites |
(Source: Sleisenger & Fordtran's GI and Liver Disease; Yamada's Textbook of Gastroenterology; Fischer's Mastery of Surgery)
3. Classification by Differentiation
Well-Differentiated NETs (G1, G2, G3)
- Retain resemblance to normal endocrine cells
- Organoid, trabecular, or glandular architecture
- Uniform nuclei, "salt-and-pepper" chromatin
- Positive for neuroendocrine markers: chromogranin A, synaptophysin, INSM1
- Express somatostatin receptors (targetable with SSA/PRRT)
Poorly Differentiated NEC (G3 only)
- Two subtypes:
- Small cell NEC - analogous to pulmonary small cell carcinoma; scant cytoplasm, nuclear molding, crush artifact
- Large cell NEC - large cells, prominent nucleoli, necrosis
- Highly aggressive; median survival < 1 year with metastatic disease
- RB1, TP53 mutations common
- Does NOT use AJCC staging for pancreatic tumors; follows exocrine pancreatic cancer staging
MiNEN (Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm)
- Each component (NE + non-NE) must constitute ≥30% of the tumor
- Common combinations: NEC + adenocarcinoma (e.g., colorectum)
- Graded based on the individual grade of each component
4. Functional Classification
GEP-NETs are also classified as functional or non-functional based on hormone secretion causing clinical symptoms:
| Functional NET | Hormone | Syndrome |
|---|---|---|
| Insulinoma | Insulin | Whipple's triad (hypoglycemia) |
| Gastrinoma | Gastrin | Zollinger-Ellison syndrome |
| VIPoma | VIP | Watery diarrhea, hypokalemia, achlorhydria (WDHA/Verner-Morrison) |
| Glucagonoma | Glucagon | Necrolytic migratory erythema, diabetes |
| Somatostatinoma | Somatostatin | Diabetes, steatorrhea, cholelithiasis |
| Carcinoid | Serotonin/other | Carcinoid syndrome (flushing, diarrhea, bronchospasm) |
- Non-functional NENs are the majority (60-90% of pNETs) - often discovered incidentally; may produce bioactive substances without clinical syndrome
5. Site-Specific Features
| Location | Embryological Origin | Common Hormones | Notes |
|---|---|---|---|
| Stomach | Foregut | Gastrin, histamine | ECL cell type; associated with H. pylori, atrophic gastritis, MEN-1 |
| Duodenum | Foregut | Gastrin, somatostatin | Most gastrinomas arise here (Zollinger-Ellison) |
| Pancreas | Foregut | Insulin, glucagon, gastrin, VIP | Wide functional range; MEN-1 association |
| Jejunum/Ileum | Midgut | Serotonin | Most common site; mesenteric desmoplasia; carcinoid syndrome |
| Appendix | Midgut | Serotonin | < 2 cm = benign behavior; most common appendiceal tumor |
| Colorectum | Hindgut | PP, glucagon | Rectal NETs often incidental; usually non-functional |
6. TNM Staging
Staging is site-specific and follows ENETS/AJCC 8th edition guidelines:
- Well-differentiated PNETs use a dedicated AJCC 8th edition TNM staging distinct from exocrine pancreatic cancer (because applying exocrine staging significantly underestimates survival)
- Poorly differentiated PNECs use the AJCC TNM for exocrine pancreatic cancer
- GI-NETs at various sites (stomach, small intestine, appendix, colon/rectum) each have their own ENETS/AJCC site-specific staging
General TNM principles:
- T - tumor size and local invasion extent
- N - regional node involvement
- M - distant metastases (most commonly liver)
7. Inherited Syndromes Associated with GEP-NETs
| Syndrome | Gene | Main NEN Association |
|---|---|---|
| MEN-1 (Werner) | MEN1 (chr 11q13) | Pancreaticoduodenal NETs (esp. gastrinoma), pituitary adenomas |
| VHL syndrome | VHL | Non-functional pNETs |
| Tuberous sclerosis | TSC1/TSC2 | pNETs (rare) |
| NF-1 | NF1 | Duodenal somatostatinomas |
Summary: Key Points
- NEN is the umbrella term; subdivided into NET (well-differentiated) and NEC (poorly differentiated)
- Grading (G1/G2/G3) is based on Ki-67 index and mitotic count - the higher of the two determines grade
- The 2017 WHO update added well-differentiated G3 NET as distinct from poorly differentiated G3 NEC - a clinically important distinction
- MiNEN requires ≥30% of each component; each is graded separately
- Functional classification (functional vs. non-functional) is independent of grade/differentiation
- Site-specific TNM staging applies; poorly differentiated PNECs follow exocrine pancreatic staging
Sources:
- Sleisenger & Fordtran's Gastrointestinal and Liver Disease, Table 34.2a/b (2010 and 2017 WHO classifications)
- Yamada's Textbook of Gastroenterology, 7th ed., Table 80.2 (GEP-NET WHO classification)
- Fischer's Mastery of Surgery, 8th ed., Table 185.1 (panNEN classification with MiNEN)
- Current Surgical Therapy, 14th ed. (WHO nomenclature: panNEN/panNET/panNEC)
- Rindi G et al: Overview of the 2022 WHO classification of neuroendocrine neoplasms, Endocrine Pathology 33:115-154, 2022
This is a shared conversation. Sign in to Orris to start your own chat.